BYSI News and Press, BeyondSpring Inc. From 06/02/20

NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abst...

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Pate...

BeyondSpring Inc. (BYSI) Q4 2019 Earnings Conference Call April 30, 2020 08:00 AM ET Company Participants Caitlin Kasunich - Senior Vice President, KCSA Strategic Communications Lan Huang - Co-Founder, Chairman & Chief Executive Officer Ramon Mohanlal - Executive Vice Preside...

Image source: The Motley Fool. BeyondSpring Inc.   (NASDAQ: BYSI) Q4 2019 Earnings Call Apr 30, 2020 , 9:00 a.m. ET Operator Continue reading

NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on F...

BeyondSpring (NASDAQ: BYSI ): Q4 GAAP EPS of -$0.52 misses by $0.12 . More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - - Initiated NDA Rolling Submission for Plinabulin for CIN in China in Q1 2020 - - On Track to Report Interim Analysis of Study ...

BeyondSpring ( BYSI +4.5% ) announces that the FDA has signed off on changing the primary endpoint of its Phase 3 clinical trial, Study 106 , evaluating lead drug Plinabulin for the prevention of chemo-induced neutropenia (abnormally low levels of a type of white blood cell called neutr...

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BeyondSpring Inc. (NASDAQ: BYSI) please note that in the fifth paragraph of the release, the correct percentage in the second sentence is 40.9, not 37.5 as previousl...

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a New York-based global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that,...